Enovis (NYSE:ENOV) Given New $40.00 Price Target at BTIG Research

Key Points

• BTIG Research raised Enovis’s price target to $40 from $39 and maintained a “buy” rating, implying 55.75% upside from the stock’s $25.68 price.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and average price target of $42.00; UBS holds the highest target at $51.00.
• Enovis exceeded quarterly expectations with EPS of $0.90 versus the $0.85 consensus and revenue of $582.78 million, up 3.2% year over year, despite reporting a negative net margin.

Enovis (NYSE:ENOV - Get Free Report) had its target price increased by equities researchers at BTIG Research from $39.00 to $40.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. BTIG Research's target price suggests a potential upside of 55.75% from the stock's current price.

A number of other equities analysts also recently commented on ENOV. Wells Fargo & Company cut their price objective on Enovis from $42.00 to $40.00 and set an "overweight" rating on the stock in a report on Friday, May 8th. Wall Street Zen raised shares of Enovis from a "hold" rating to a "buy" rating in a research report on Monday, July 6th. UBS Group reissued a "buy" rating and issued a $51.00 price objective (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. BMO Capital Markets began coverage on shares of Enovis in a report on Wednesday, July 8th. They set an "outperform" rating and a $29.00 target price on the stock. Finally, Evercore set a $32.00 price target on Enovis in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $42.00.

Enovis Price Performance

ENOV stock traded down $4.50 on Thursday, reaching $25.68. The company had a trading volume of 1,517,256 shares, compared to its average volume of 1,087,456. Enovis has a 1 year low of $19.14 and a 1 year high of $34.28. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The company's fifty day moving average is $24.47 and its 200 day moving average is $23.93. The company has a market cap of $1.48 billion, a P/E ratio of -1.29 and a beta of 1.34.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company had revenue of $582.78 million for the quarter, compared to analysts' expectations of $581.84 million. During the same period last year, the company earned $0.79 EPS. The firm's revenue for the quarter was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts forecast that Enovis will post 3.12 earnings per share for the current year.

Insider Activity

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares of the company's stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders acquired a total of 4,200 shares of company stock valued at $92,084 over the last ninety days. Corporate insiders own 2.90% of the company's stock.

Hedge Funds Weigh In On Enovis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its holdings in shares of Enovis by 1.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company's stock valued at $90,156,000 after acquiring an additional 51,201 shares during the period. Rubric Capital Management LP purchased a new stake in shares of Enovis in the third quarter valued at $83,435,000. Paradigm Capital Management Inc. NY boosted its position in shares of Enovis by 70.2% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company's stock worth $40,420,000 after buying an additional 732,917 shares during the period. River Road Asset Management LLC grew its holdings in shares of Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company's stock valued at $39,621,000 after buying an additional 46,289 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in Enovis by 38.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company's stock valued at $24,430,000 after buying an additional 287,687 shares during the period. 98.45% of the stock is owned by institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source